Search

everythinglearnresearchcommunity

for

Search:↓

Urinary PSA could be an early marker for enlarged prostate.

Hydroxychloroquine may help treat benign prostatic hyperplasia by reducing inflammation and promoting cell death.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.

Combination therapy for BPH is more effective in certain men but may not be cost-effective due to minimal impact and potential side effects.

5 alpha-reductase inhibitors like finasteride may lower prostate cancer risk and improve cancer screening.

Combining medications is more effective for treating benign prostatic syndrome symptoms.

Dutasteride works better than finasteride for preventing and treating prostate cancer.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

The conclusion is that primary scarring alopecia is a complex condition that requires early and accurate diagnosis for effective treatment.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

Hair loss gene linked to prostate issues.

Drinking a lot of alcohol increases the risk of prostate cancer and can worsen the condition.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Many patients with benign prostatic hyperplasia experience high anxiety and residual symptoms, needing better anxiety management.

Most white Spanish women have a widow's peak, and their hairline measurements could help in hair restoration surgery.

Finasteride reduces prostate size, improves urination, and slows prostate cancer progression.

Finasteride effectively treats enlarged prostate and male baldness, improves symptoms of hirsutism in women, but doesn't work for acne, and may delay prostate cancer progression with few side effects.

Incidental prostate cancer was found in 4.89% of patients undergoing surgery for benign prostatic hyperplasia.

Finasteride lowers PSA levels and prostate size, requiring adjusted PSA interpretation for accurate cancer screening.

Finasteride lowers PSA levels about the same whether taken at 1 mg or 5 mg daily.

After prostate removal surgery, higher initial prostate size was linked to higher urethral PSA levels and more severe male pattern baldness.

COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.

Poor sleep is linked to a higher risk of developing and worsening urinary problems in men.

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

Low-dose finasteride lowers PSA levels, which can make prostate cancer harder to detect.

Dutasteride reduces DHT more effectively than finasteride.

Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.

Doxazosin alone or combined with finasteride improves prostate symptoms better than finasteride alone, without extra benefits.

Low testosterone does not prevent prostate cancer in men with type 1 diabetes.